As Bitcoin Soars, Luxury Brands Consider Accepting Crypto Payments

/in /tarafından

The recent surge in Bitcoin’s value has prompted luxury brands and retailers to explore cryptocurrency as a payment method, aiming to tap into the growing wealth of crypto investors and position themselves as innovative. While early adopters such as LVMH’s Hublot and Tag Heuer, along with Kering-owned Gucci and Balenciaga, have dabbled in crypto payments, the interest among high-end brands is accelerating.

One notable move came from French luxury department store Printemps, which partnered with Binance, the world’s largest crypto exchange, and French fintech firm Lyzi, to accept Bitcoin and Ethereum payments in its French locations. This step makes Printemps the first European department store to embrace cryptocurrency payments, a development generating significant interest from other brands.

“We’ve received numerous inquiries,” said David Princay, president of Binance France, noting ongoing talks with additional luxury labels. Similarly, S.T. Dupont, a maker of luxury lighters and pens, plans to roll out crypto payment options at two Paris locations before the holiday season.

Beyond fashion, the trend has extended into experiential luxury. For example, Virgin Voyages recently launched a $120,000 annual pass for its cruise ships, accepting Bitcoin as payment.

While cryptocurrencies’ high volatility and regulators’ warnings about their risks have been barriers to broader adoption, a more favorable regulatory environment under U.S. President-elect Donald Trump has bolstered confidence in digital currencies. Analysts from S&P suggest that blockchain innovation and greater financial market integration may enhance cryptocurrencies’ predictability, opening new opportunities for businesses.

Branding and Reaching Younger Clients

For luxury brands, embracing cryptocurrencies is as much about innovative branding as it is about new revenue streams. Digital assets can help brands shed their “stuffy” image and appeal to younger, tech-savvy clientele, said Andrew O’Neill, a digital assets analyst at S&P Global Ratings.

Notably, Balenciaga has released a luxury leather cardholder specifically designed to hold “Stax” hardware by crypto wallet company Ledger. The accessory, priced at €350 ($368), comes with an NFC chip and hardware storage for cryptocurrency. Ledger’s products range from $79 for the USB-style Nano wallet to $399 for its high-end Stax wallet.

Luxury conglomerates like Kering have also embraced a forward-looking approach. Gregory Boutte, Kering’s chief client and digital officer, described their strategy as “test and learn” rather than waiting for trends to mature. Gucci, Kering’s flagship brand, has been accepting 10 cryptocurrencies for purchases in the U.S. since 2022.

Expanding Markets and Evolving Preferences

Printemps plans to expand its crypto payment options to its upcoming New York City flagship store, set to open in March 2025 in the Wall Street district. Gucci and Tag Heuer were among the first brands to adopt crypto payments in the U.S. following Bitcoin’s surge in late 2021.

While some crypto investors appreciate the convenience of using digital currencies for luxury purchases, others remain indifferent to brand loyalty. Influencer and crypto investor Eunice Wong shared that she used cryptocurrency to buy several high-end watches, including an Audemars Piguet Royal Oak model. However, Wong prefers the secondary market over traditional retail, citing the speed and ease of purchase as her priorities.

Despite the challenges, luxury brands see crypto payments as a way to attract new customers, diversify revenue streams, and position themselves as leaders in innovation during a time of economic slowdown.

 

Eli Lilly’s Alzheimer’s Treatment Approved in China

/in /tarafından

China’s medical regulator has approved Eli Lilly’s Kisunla, an Alzheimer’s treatment for early-stage disease, offering patients an additional therapeutic option after the approval of Leqembi, developed by Eisai and Biogen, earlier this year. This marks China’s entry into a select group of major markets—including the United States, Japan, and the UK—where Kisunla is approved, Eli Lilly announced on Tuesday.

Kisunla, like Leqembi, targets the clearance of beta-amyloid, a protein linked to Alzheimer’s disease, from the brain. In a late-stage clinical trial, Kisunla demonstrated a 29% reduction in the progression of memory and cognitive decline compared to a placebo. However, the treatment carries safety concerns, with reports of brain swelling in nearly 25% of patients and brain bleeding in approximately 33%, though most cases were deemed mild.

In response to these risks, Kisunla’s U.S. prescribing label includes the FDA’s strongest “boxed” safety warning, similar to Leqembi’s label. Lilly has addressed concerns by introducing a gradual dosing schedule, which has been shown to reduce the likelihood of severe brain swelling.

A key distinction between Kisunla and Leqembi lies in their dosing approach. Kisunla offers finite dosing, allowing patients to discontinue the treatment once brain scans confirm the absence of amyloid plaques, whereas Leqembi does not.

Kisunla is currently under review by the European Union’s drug regulator. In contrast, Leqembi was rejected by the EU earlier this year due to concerns that the risks of brain swelling outweighed its modest benefits in slowing cognitive decline.

According to the World Health Organization, Alzheimer’s is the leading cause of dementia, accounting for 60%-70% of cases globally.

 

EU to Review Novo Nordisk’s Ozempic Over Eye Disease Concerns

/in /tarafından

The European Medicines Agency (EMA) announced it would evaluate two recent Danish studies linking Novo Nordisk’s diabetes medication, Ozempic, to an increased risk of a rare eye disease known as non-arteritic anterior ischemic optic neuropathy (NAION).

The studies, published earlier this week, revealed that Ozempic could more than double the likelihood of patients with type 2 diabetes developing NAION. This condition, which can lead to sudden vision loss, occurs when blood flow to the optic nerve is reduced.

Previously, the EMA had reviewed other research but found no conclusive evidence connecting Ozempic to the rare eye disease. However, the agency stated late Tuesday that the findings from these new Danish studies may provide significant new information, prompting further investigation.

Ozempic, which is also widely prescribed for weight loss, has become one of Novo Nordisk’s most successful drugs, contributing to the company’s dominant position in the diabetes and obesity treatment market.

The EMA did not specify a timeline for the review but emphasized its commitment to ensuring the safety of all medications in the EU market.